Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceSTU:0ME +3.56%70 Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus rates STU:0ME with a GF Score™ of 70/100 and a GF Value™ of €45.37 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Twist Bioscience ranks better than 71.78% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Twist Bioscience's Revenue for the
three
months ended in Mar. 2026 was €95.8 Mil. Twist Bioscience's average Accounts Receivable for the
three
months ended in Mar. 2026 was €49.1 Mil.
Hence, Twist Bioscience's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.95.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Twist Bioscience Receivables Turnover Related Terms
Twist Bioscience Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0ME vs BLLN, SHC, RDNT: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (STU:0ME) has a Receivables Turnover of 1.95 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Twist Bioscience and its competitors. According to the industry distribution chart, Twist Bioscience ranks #57 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 28.2%.
Is Twist Bioscience's Receivables Turnover too high?
Twist Bioscience's current Receivables Turnover is 1.95. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Twist Bioscience's value of 1.95 is 63.8% below this industry median. Based on the distribution chart, Twist Bioscience ranks #57 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Receivables Turnover compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #57 out of 202 companies for Receivables Turnover. This puts Twist Bioscience in the upper half of its industry. The industry median Receivables Turnover is 5.38. Twist Bioscience's value of 1.95 is 63.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Receivables Turnover of 1.95 is 63.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Twist Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Receivables Turnover is 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (STU:0ME) is currently considered Significantly Overvalued. The stock's GF Value™ is €45.37, compared to a current price of €94.86 — trading 109.1% above its estimated fair value. The current Receivables Turnover is 1.95 and 63.8% below the Medical Diagnostics & Research industry median of 5.38. Twist Bioscience's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Twist Bioscience (STU:0ME), the current Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (STU:0ME) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €94.86 is trading 109.1% above its estimated GF Value™ of €45.37.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for STU:0ME:
Receivables Turnover: 1.95
GF Value™: €45.37 vs. price of €94.86 (109.1% above fair value)
Industry Position: 63.8% below the Medical Diagnostics & Research median (#57 of 202)
No single metric tells the full story. See the STU:0ME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
70GF Score
Get the complete analysis for STU:0ME
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0ME has been successfully added to your 
